ReShape Lifesciences® Reports Third Quarter Ended ...

ReShape Lifesciences® Reports Third Quarter Ended September

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update ... IRVINE, Calif., Nov. 14, ...

ReShape Lifesciences® to Announce Financial Results for the Third ...

(Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial ...

Reshape Lifesciences Inc (RSLS) Q3 2024 Earnings Call Highlights

Reshape Lifesciences Inc (RSLS) reports a 6% revenue increase for Q3 ... ended September 30, 2024, compared to the same period in 2023.

ReShape Lifesciences® Reports Third Quarter Ended September ...

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and ... · This page requires Javascript.

ReShape Lifesciences® to Announce Financial Results for the Third ...

(Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial ...

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ETCompany ParticipantsMichael Miller ...

Press Releases - ReShape Lifesciences

November 12, 2024. ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update · November 12 ...

ReShape Lifesciences Inc. SEC 10-Q Report - TradingView

ReShape Lifesciences Inc. reported a revenue of $2.3 million for the third quarter of 2024, marking a 6.4% increase compared to the same period ...

ReShape Lifesciences (RSLS) Sets Q3 2024 Earnings Call with ...

ReShape Lifesciences (Nasdaq: RSLS) announced it will release its third quarter 2024 financial results on Thursday, November 14, 2024, ...

ReShape Lifesciences® Reports Third Quarter Ended September ...

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan · $1.3 million , compared to ...

Exhibit 99.1 - SEC.gov

Exhibit 99.1. . . ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update · SAN CLEMENTE, Calif., November 14, 2022 .

ReShape Lifesciences® Reports Third Quarter Ended September ...

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan. Our Vision. Leading the way as the ...

ReShape Lifesciences® Reports Third Quarter Ended September

Research and development expenses for the nine months ended September 30, 2023, decreased by $0.5 million to $1.6 million, compared to $2.1 ...

ReShape Lifesciences Inc. Reports Earnings Results for the Third ...

ReShape Lifesciences Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, ...

ReShape Lifesciences Stock News (RSLS) - Page 4 - Public.com

... Results for the First Quarter Ended March 31, 2022 and ... ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results.

ReShape Lifesciences Announces Third Quarter 2019 Financial ...

Recognized revenue of $3.5 million in the third quarter of 2019 · Fully completed the global distribution transition of the LAP-BAND® System ...

Quarterly Results - Moderna

Q3 2024 Report. Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates. Reports third quarter revenues of $1.9 billion, GAAP net ...

Edwards Lifesciences Reports Third Quarter Results

“Third quarter total company sales growth from continuing operations of 10% reflected strong contributions from both TAVR and our rapidly ...

ReShape Lifesciences: Overview

September 19, 2024. ReShape Lifesciences Announces 1-for-58 Reverse Stock Split · August 14, 2024. ReShape Lifesciences® Reports Second Quarter Ended June 30, ...

RSLS | ReShape Lifesciences® Reports Third Quarter Ended ...

RSLS | ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update.